此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

正电子发射断层扫描 (PET) 引导立体定向体部放射治疗寡进展非小细胞肺癌、黑色素瘤和肾细胞癌

2026年11月2日 更新者:City of Hope Medical Center

生物引导立体定向放射治疗寡进展非小细胞肺癌、黑色素瘤和肾细胞癌的 II 期随机对照试验

This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. A PET scan is an imaging test that looks at your tissues and organs using a small amount of a radioactive substance. It also checks for cancer and may help find cancer remaining in areas already treated. Using a PET scan for SBRT planning may help increase the dose of radiation given to the most resistant part of the cancer in patients with oligoprogressive NSCLC, melanoma, and RCC.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. PET adaptive SBRT is both feasible and safe and allows for a higher total dose of radiation through an inter-fraction simultaneous integrated boost (SIB) based on inter-fraction PET uptake, leading to improved local control outcomes compared to current standard SBRT planning without a SIB.

SECONDARY OBJECTIVES:

I. Determine the duration of local and distant control followed PET adaptive SBRT treatment compared to standard external beam radiation therapy (EBRT).

II. Evaluate the utility of measuring circulating tumor deoxyribonucleic acid (DNA) (ctDNA) before, during and after SBRT in conjuction with biological imaging to assess early disease response.

III. Identify genomic predictors to predict for distant progression. IV. Determine durability of current systemic therapy with SBRT to oligoprogressive sites.

EXPLORATORY OBJECTIVES:

I. Biomarker changes based on ctDNA before, during and after treatment. II. Changes in fludeoxyglucose (FDG) uptake with SBRT and combined checkpoint inhibitor during and after treatment and correlation with local and distant control.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo 5 SBRT treatments every other day on study. Patients also undergo computed tomography (CT) or PET/CT and blood collection throughout study.

ARM II: Patients undergo 3 SBRT treatments every other day week 1, undergo PET/CT and replanning one month post SBRT, then undergo 2 additional treatments with SIB on study. Patients also undergo CT or PET/CT and blood collection throughout study.

研究类型

介入性

注册 (估计的)

32

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • California
      • Duarte、California、美国、91010
        • 招聘中
        • City of Hope Medical Center
        • 首席研究员:
          • Arya Amini
        • 接触:
      • Irvine、California、美国、92618
        • 招聘中
        • City of Hope at Irvine Lennar
        • 接触:
          • Arya Amini
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Documented informed consent of the participant and/or legally authorized representative

    • Assent, when appropriate, will be obtained per institutional guidelines
  • Agreement to allow the use of archival tissue from diagnostic tumor biopsies

    • If unavailable, exceptions may be granted with study principal investigator (PI) approval
  • Age: >= 18 years

  • Eastern Cooperative Oncology Group (ECOG) =< 2

  • Histologically or cytologically confirmed NSCLC with 1-5 sites of disease progression while on or following systemic therapy with a checkpoint inhibitor with or without chemotherapy for at least 3 months with radiographic evidence of progression based on Response Evaluation Criteria in Solid Tumors (RECIST) or Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST)

  • Lesion(s) must all be amenable to SBRT which will be determined by the radiation oncologists. Active lesions should be a minimum size of >= 1 cm

  • Primary tumor should be controlled for > 3 months in the metachronous setting; for synchronouos progression of the primary and oligoprogressive site(s), the primary should be treated with curative/local control intent

  • Patients eligible for the study must have at least one lesion for which the planned radiation dose achieves a biologic effective dose (BED) < 100 (alpha/beta = 10) due to organs at risk and dose constraints

  • If the clinical scenario deem that other forms of local therapy may be more suitable for the metastatic disease, such as surgical resection and interventional radiology-guided ablation, patients would be able to undergo other forms of local therapy after discussion with the study PI but at least one lesion must be treated with SBRT in this scenario

  • Patients with brain metastases can be included but brain metastases must be treated prior to enrollment and are not considered as a site of oligoprogression

  • Life expectancy >= 3 months in the opinion of the treating investigators

Exclusion Criteria:

  • Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements
  • Those not eligible for SBRT after review by a radiation oncologist
  • Unable to undergo a Pet/CT or do not have Pet active disease
  • Pregnant and/or breastfeeding women are excluded from this study as these agents may have the potential for teratogenic or abortifacient effects. Female patients of childbearing potentially must have a negative urine or serum pregnancy test within 72 hours prior to receiving therapy
  • Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:ARM I: (standard care SBRT)

Patients undergo 5 SBRT treatments every other day on study. Patients also undergo CT or PET/CT and blood collection throughout study.

Ancillary studies

Undergo PET

其他名称:
  • 医学成像、正电子发射断层扫描
  • 宠物
  • 宠物扫描
  • 正电子发射断层扫描
  • 质子磁共振波谱成像
  • PT

Undergo CT or PET/CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描

Undergo blood collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Undergo SBRT

其他名称:
  • SBRT
  • 军刀
  • 立体定向消融性身体放射治疗
实验性的:ARM II: (PET guided SBRT)

ARM II: Patients undergo 3 SBRT treatments every other day week 1, undergo PET/CT and replanning one month post SBRT, then undergo 2 additional treatments with SIB on study. Patients also undergo CT or PET/CT and blood collection throughout study.

Ancillary studies

Undergo PET

其他名称:
  • 医学成像、正电子发射断层扫描
  • 宠物
  • 宠物扫描
  • 正电子发射断层扫描
  • 质子磁共振波谱成像
  • PT

Undergo CT or PET/CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描

Undergo blood collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Undergo SBRT

其他名称:
  • SBRT
  • 军刀
  • 立体定向消融性身体放射治疗

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Feasibility and safety of positron emission tomography (PET) adaptive stereotactic body radiation therapy (SBRT)
大体时间:At completion of SBRT up to 5 weeks

Feasibility and safety of biologically-guided adaptive planning based on the standardized uptake value (SUV) on pre-treatment and inter-fraction FDG-PET/CT to guide SBRT dose-escalation with a simultaneous integrated boost (SIB) delivered to areas of higher activity in patients with oligoprogressive (1-5 sites) disease when compared to the current standard SBRT planning without inter-fraction adaptive planning, with the goal of demonstrating that PET-adaptive inter-fraction planning can improve total dose delivered over the course of treatment. We will be measuring the difference in total radiation dose in Gy between the two arms with the goal of achieving an absolute dose of 10 Gy or higher.

At completion of SBRT up to 5 weeks

次要结果测量

结果测量
措施说明
大体时间
总生存期
大体时间:长达 12 个月
长达 12 个月
下一次全身治疗的时间
大体时间:长达 12 个月
长达 12 个月
Time to progression
大体时间:Up to 12 months

Defined as time of randomization to disease progression at any site or death. Assessed using the modified Response Evaluation Criteria in Solid Tumors (mRECIST).

Up to 12 months
Quality of life (QOL)
大体时间:Up to 12 months

Patient reported outcomes using the Functional Assessment of Cancer Therapy - G. Baseline changes in reported QOL will be summarized. Repeated QOL assessments will be tabulated and graphically displayed to describe the changes of QOL outcomes over time, no formal hypothesis testing is planned. An evaluation by dose, response and other characteristics may also be considered. For quantitative QOL scales, data will be represented using means/ medians, histogram/ boxplots. The area under curve will be used as a summary score for each patient. These can then be averaged across groups for informal assessment. Standard imputation methods will be used to deal with a large proportion of missing data.

Up to 12 months
Incidence of adverse events
大体时间:At 3, 6, and 12 months following radiation therapy

Clinician documented toxicity using common terminology for adverse events version 5.

At 3, 6, and 12 months following radiation therapy
Local control rates
大体时间:Up to 12 months

Assessed using the mRECIST.

Up to 12 months
Dose delivered
大体时间:Up to 12 months

Defined as the dose delivered in the experimental group for the first 3 fractions versus the dose given for the last 2 fractions.

Up to 12 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Arya Amini、City of Hope Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月29日

初级完成 (估计的)

2028年2月3日

研究完成 (估计的)

2028年2月3日

研究注册日期

首次提交

2023年3月17日

首先提交符合 QC 标准的

2023年4月13日

首次发布 (实际的)

2023年4月26日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月2日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅